2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

35
November 8-13, 2012 Anaheim, California acaai.org The American College of Allergy, Asthma & Immunology 2012 Annual Scientific Meeting © D i s n e y REGISTRATION INFORMATION

description

 

Transcript of 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Page 1: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

November 8-13, 2012Anaheim, California

acaai.org

The American College of Allergy, Asthma & Immunology

2012 Annual Scientifi c Meeting

© Disney

REGISTRATION INFORMATION

Page 2: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

2

ACAAI 2012 Annual Scientific Meeting

Over the Horizon: Expanding Expertise

Housing and General Information . . . . . . . . . . . . . . . . . . . . . . . .3Education Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4Maintenance of Certification . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5Pre-Meeting Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6Annual Literature Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7Friday Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8House of Delegates Meeting & Town Hall Forum . . . . . . . . .9General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11Meet the Professor Breakfasts . . . . . . . . . . . . . . . . . . . . . . . . . .16Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17Fellows-in-Training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23Advanced Practice Health Care Providers Course . . . . . . . .24Allied Health Professionals Course . . . . . . . . . . . . . . . . . . . . . .25Alliance Programs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27Fundraising Dinner . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28Social Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29Things To Do In Anaheim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30

Table of Contents

The theme of the Anaheim meeting is Over the Horizon:Expanding Expertise. Our practices are changing, but we have

expertise that allows us to expand intoareas of medical management that are justover the horizon. It is my goal for thismeeting to increase our proficiency inareas we have knowledge about tomanage patients as effectively, or better,than other practitioners.

In keeping with themeeting theme, theThursday InternationalFood Allergy

Conference will include sessions addressing the role of theallergist in managing eosinophilic gastrointestinal disorders,expanding diagnosis and the management armamentarium,interactions with other specialists, and skin and patch testing.

Although many of the plenary sessions are directed to areaspresently peripheral to what’s central in many practices, theProgram Committee and I have not forgotten the importanceof asthma. The opening plenary, “Managing Asthma Patients

in the 21st Century,” presents an intriguing perspective onasthma heterogeneity, the role of vitamin D, FeNO, and newdevelopments. Another session, “When Shortness of Breath IsNot Asthma,” addresses autoimmune and other interstitiallung diseases, and the impact of swallowing disorders andaspiration. This year, the Great Raft Debate topic isAnaphylaxis Mediators – which should prove to be anexciting and provocative session. Other sessions focus oncontact dermatitis, urticaria and disturbed sleep syndromes.

Meeting highlights include the perpetually popular FridayLiterature Review, Workshops and Meet the ProfessorBreakfasts. Special courses are offered for Advanced PracticeHealth Care Providers and Allied Health Professionals.

I am confident that after attending this year’s AnnualMeeting, members will come away with a heightenedawareness of where they can expand their expertise, and inso doing, expand and keep their practices healthy. See youin Anaheim!

Richard W. Weber, MD, FACAAIProgram Chair

Richard Weber, MD, FACAAIPresident-Elect and Program Chair

Anaheim is the perfect setting for the ACAAI Annual Meeting

What Is This?This symbol is called a “QR Code”and it enables your smartphoneto instantly access the ACAAIAnnual Meeting website. To useit, you’ll need to download a freeQR app (available from your phone’sapplication store) if you don’t already have one. Next, take aphoto of the QR Code and you’ll be instantly connected tothe College’s meeting website.

ACAAI Annual Meetinghttp://www.acaai.org/annual_meeting/Pages/default.aspx

Register online atwww.acaai.org

Page 3: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Housing & General Information

3

Housing InformationThe ACAAI Annual Meeting will be held at the Anaheim ConventionCenter and the Anaheim Marriott Hotel. The convention hotelsinclude the Anaheim Marriott and Hilton Anaheim hotels.Both hotels are located directly across the street from theconvention center.

Hotel reservations must be made through the ACAAI HousingBureau either online via the internet, by phone, fax or mail usingthe housing form. A credit card guarantee is required. The hotelswill not accept reservations directly.

For best availability, make your reservation via the internet atwww.acaai.org.

Internet: www.acaai.org

Phone: (714) 765-8868

Fax: Fax a completed housing form, one form per room, to:(714) 776-2688

Mail: Mail a completed housing form to:ACAAI Housing Bureau800 W Katella Ave.P.O. Box 4270Anaheim, CA 92803

Room Rates: Marriott $229 Single$249 Double

Hilton $235 Single / Double

For additional housing questions, please call the ACAAI HousingBureau at (714) 765-8868 or email to:[email protected].

The deadline for reservations is Wednesday, October 3, 2012.

Hotel reservations/rate availability are not guaranteed after theroom block is full or after October 3, 2012. Please register early –only a limited number of rooms are available at each hotel.

Child Care ServicesPlease contact the concierge at the hotel at which you are stayingfor a list of bonded independent baby-sitters and baby-sittingagencies.

Note: Children under 12 are not admitted to the ScientificSessions or the exhibit area.

Anaheim InformationVisit http://microsite.anaheimoc.org/american-college-allergy-asthma-immunology for information and local attractions.The average temperature in November ranges from a low of 52°F toa high of 76°F.

Disneyland® Advance PurchaseDiscounted TicketsACAAI has made arrangements with Disneyland® for advancepurchase of specially-priced Disneyland® Resort Tickets. Visit the onlineDisney ticket store at www.disneyconventionear.com/ZMAK12A.

Annual Meeting GeneralRegistration FeesYour registration fee includes Plenary, Symposia, ConcurrentSessions, Exhibit Hall and various social events. It does not includethe optional Fundraising Dinner, MTP Breakfasts, Workshops or othercourses with a separate registration fee.

Limited Seating for SymposiaBecause of limited seating capacity, admission to all symposia willbe on a first-come, first-served basis. Pre-registration is not requiredunless otherwise noted.

Young PhysiciansSessions that may be of special interest to young physicians areidentified throughout this program with a .Y

Photo courtesy of AOCVCB

Page 4: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Education Information

4

This activity is supported by educational grants from commercialinterests. Complete information will be provided to participants prior tothe activity.

Target Audience• All practicing allergists/immunologists

• Fellows in allergy/immunology training programs

• Primary care physicians who care for allergy patients

• Allied health professionals in the field of allergy and immunology

Overall Educational ObjectivesAt the conclusion of this activity, participants should be able to:

• Identify major advances in key areas of cutting-edge research inimmunologic mechanisms and allergic responses includinganaphylaxis and pathophysiology of the upper airways, lungs, eyes,skin, and gastrointestinal tract

• Demonstrate knowledge of basic processes linking molecular andcellular biology and genetics with allergic pathophysiology andimmunodeficiency

• Translate emerging clinical science principles to clinical practice inpatients with allergic and immunologic disorders

• Evaluate and implement state-of-the-art diagnostic andtherapeutic strategies for treating patients with allergic andimmunologic diseases

• Explain the impact of environmental exposures and externalinfluences on patients with allergic disorders

• Recognize emerging trends in the prevalence of allergic andimmunologic disorders and discuss their impact on public health

• Evaluate the impact of new diagnostic and therapeutic strategieson healthcare costs and outcomes

• Discuss processes, tools and technologies for the efficient allergyand immunology practice

Accreditation and DesignationThe American College of Allergy, Asthma &Immunology (ACAAI) is accredited by theAccreditation Council for Continuing Medical

Education (ACCME) to provide continuing medical educationfor physicians.

The American College of Allergy, Asthma & Immunology (ACAAI)designates this live activity for a maximum of 44 AMA PRACategory 1 Credits™. Physicians should claim only the creditcommensurate with the extent of their participation inthe activity.

This continuing medical education activity has been reviewed bythe American Academy of Pediatrics and is acceptable for amaximum of 44.00 AAP credits. These credits can be applied towardthe AAP CME/CPD Award available to Fellows and CandidateMembers of the American Academy of Pediatrics.

Photo courtesy of John Mairs/AOCVCB

Page 5: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Maintenance of Certification

5

Patient Care— the ability to provide patient care that iscompassionate, appropriate, and effective for the treatment ofhealth problems and the promotion of health:• data gathering• history taking• patient examination• diagnosis• interpretation/decision-making/assessment• management/treatment plans• preventive care• procedures

Medical Knowledge— the knowledge about established andevolving biomedical, clinical, and cognate sciences and theapplication of this knowledge to patient care:• general principles/concepts/theories• applied basic sciences• applied biomedical sciences• applied clinical knowledge• epidemiology and psychosocial behavioral sciences• population-based medicine

Practice-based Learning and Improvement— the abilityto investigate and evaluate patient care practices, appraiseand assimilate scientific evidence, and improve their patientcare practices:• benchmarks/best practices• practice related quality improvement• evidence-based practice/medicine• continuing professional development/continuingmedical education

• practice self-assessment• information technology/medical informatics• teaching and learning and lifelong learning

Interpersonal and Communication Skills— the ability todemonstrate interpersonal and communication skills that resultin effective information exchange and collaboration withpatients, their families, and other health professionals:• teaming and team leadership skills (interprofessional,multidisciplinary)

• effective communicator and listener• caring, respectful behavior• written and verbal communication skills• educating/counseling patients and family members• teaching skills

Professionalism— reflects a commitment to carrying outprofessional responsibilities, adherence to ethical principles,and sensitivity to a diverse patient population:• physician accountability• humanistic qualities (respect, compassion, integrity)• professional ethics• socio-cultural factors (sensitivity to culture, diversity, gender,age, disabilities)

• advocacy for and responsive to patient needs• commitment to excellence and quality care• mentorship and role-modeling

System-based Practice— an awareness of and responsivenessto the larger context and system of healthcare, and the ability tocall effectively on other resources in the system to provideoptimal health care:• patient safety• cost-effective care• management of resources• medical errors• continuity of care• healthcare delivery and systems of care models• utilization issues• risk management• electronic record keeping• management and leadership skills

6

5

4

3

2

1

Through its responsibility to provide quality CME to its membership, the ACAAI continues its support of the ABAI, which credentialsand evaluates allergy and immunology specialists. Since 1977, ABAI has offered its Diplomates a recertification process to demonstrate theirefforts in continuing education. In 2009, ABAI transitioned to the more comprehensive Maintenance of Certification(ABMS MOC) program.

Linking the education content of the ACAAI Annual Scientific Meetings to the MOC program is one way ACAAI helps its members provideABAI with evidence of their commitment to lifelong learning. Ultimately, CME activities for which MOC credit is awarded may be cross-referenced to the ABAI examination content outline, available on the ABAI website www.abai.org. Members are encouraged to select areasof interest from the program, which will enhance their knowledge of state-of-the-art allergy/immunology and improve the quality ofpatient care.

ACAAI will assist Allergy/Immunology Training Programs with additional curricular resources and assessment measures that may beused to help meet their requirements for assessing competency in the six core areas as designed by the ACGME. The six corecompetencies include:

Page 6: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Pre-Meeting Course Thursday, November 8

6

SEPARATE REGISTRATION FEE • SEE REGISTRATION FORM A OR REGISTER ONLINE AT WWW.ACAAI.ORG

International Food Allergy Conference8:00 am – 5:00 pm

Navigating EosinophilicGastrointestinal Disorders:The Allergist at the Helm

Moderators: Amal H. Assa’ad, MD, FACAAI andKaren A. DeMuth, MD, FACAAI

8:15 am Eosinophilic Esophagitis and Food Allergy:Where Do They Meet?Marc Rothenberg, MD, PhD, FACAAI

8:45 am Optimal Pharmacotherapy: Types and DurationSeema Aceves, MD, PhD

9:15 am Clinical Relevance of the Food-Pollen SyndromeM. Antonella Muraro, MD

9:45 am Questions & Panel Discussion

10:00 am Refreshment Break

Getting Comfortable WithOff-the-Beaten-Track Food Allergies

Moderators: Helen H. Chan, MD andBrian G. Wilson, MD, FACAAI

10:15 am Food Protein Induced Enterocolitis: RaisingAwareness Among the Primary Care PhysiciansJonathan M. Spergel, MD, PhD, FACAAI

10:45 am Spice AllergySami L. Bahna, MD, DrPH, FACAAI

11:15 am Allergy to Tree Nuts: A Rising ConcernAlessandro Fiocchi, MD

11:45 am Abstract Presentation

Noon Questions & Panel Discussion

12:15 pm Lunch Break (on own) and Poster Viewing

Expanding Our Diagnosis andManagement Armamentarium

Moderators: Sami L. Bahna, MD, DrPH, FACAAI andVivian Hernandez-Trujillo, MD, FACAAI

1:15 pm

1:45 pm Food Immunotherapy Procedures: Are WeThere Yet?A. Wesley Burks, MD, FACAAI

2:15 pm Abstract Presentations

2:45 pm Questions & Panel Discussion

3:00 pm Refreshment Break

The Allergist Among the Colleagues

Moderators: Marcella R. Aquino, MD, FACAAI andAlessandro Fiocchi, MD, FACAAI

3:15 pm Food Allergy and Atopic Dermatitis:Generating a Common Approach Withthe DermatologistLuz S. Fonacier, MD, FACAAI

3:45 pm Immunodeficiency Disguised as Food AllergyJordan S. Orange, MD, PhD, FACAAI

4:15 pm Abstract Presentations

4:45 pm Questions & Panel Discussion

Luisa Businco Memorial Lecture

Predicting the Natural History ofFood AllergyAmal H. Assa’ad, MD, FACAAI

Page 7: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Symposia Thursday, November 8

6A

Panelists:

Todd A. Mahr, MD, FACAAI

F. Estelle R. Simons, MD, FACAAI

Dana V. Wallace, MD, FACAAI

6:15 – 8:15 pm

DinnerSymposium

Debatable Issues Regarding thePrescription and Administration ofan Automatic Epinephrene Injectorfor Patients with Anaphylaxis

Moderator: Phillip L. Lieberman, MD, FACAAI

Register online atwww.acaai.org

Photo courtesy of AOCVCB; © Disney

Page 8: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Annual Literature Review Friday, November 9

7

Morning Session7:45 – 11:30 am

Moderator: James T. Li, MD, FACAAI

To help you keep abreast of the latest clinical developments in allergy and immunology, ACAAI will continue its highlysuccessful Literature Review Program, which is a review of the most important, clinically-focused literature of our specialtypublished between October 2011 and August 2012, with emphasis on clinical relevance.

Faculty includes allergy/immunology training program directors and specialists in practice.

Chair: Mark T. O’Hollaren, MD, FACAAI

7:45 am Basic Immunology and Genetics for the AllergistDavid A. Khan, MD, FACAAI

8:15 am Anaphylaxis, Drug Allergy and Stinging InsectHypersensitivityAnthony Montanaro, MD, FACAAI

8:45 am Occupational and Environmental AllergyMark S. Dykewicz, MD, FACAAI

9:15 am Asthma and Lower Respiratory DiseasesJames T. Li, MD, FACAAI

10:00 am Urticaria, Angioedema and Other Skin DisordersGerald W. Volcheck, MD, FACAAI

10:30 am Update in Pediatric AllergyJohn M. Kelso, MD, FACAAI

11:00 am Update on Infectious Diseases, Antimicrobials,and VaccinesMichael S. Blaiss, MD, FACAAI

11:30 am Lunch (on own)

1:00 pm ImmunotherapyDavid I. Bernstein, MD, FACAAI

1:30 pm Food and Additives AllergyVivian Hernandez-Trujillo, MD, FACAAI

2:00 pm Population Management of AsthmaWilliam W. Crawford, MD

2:45 pm Rhinitis and SinusitisRichard A. Nicklas, MD, FACAAI

3:15 pm The Ten Best Articles in the Specialty of AllergyMark T. O’Hollaren MD, FACAAI

3:40 pm Questions and Discussion

Everything You Should Have Read Last Year, but Didn’t!7:45 am – 3:45 pm

Afternoon Session1:00 – 3:45 pm

Moderator: Mark T. O’Hollaren, MD, FACAAI

SEPARATE REGISTRATION FEE • SEE REGISTRATION FORM B OR REGISTER ONLINE AT WWW.ACAAI.ORG(YOU MUST BE REGISTERED FOR THE ANNUAL MEETING TO ENROLL IN THE ANNUAL LITERATURE REVIEW.)

Page 9: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Symposia Friday, November 9

8

Epidemiology and Characterizationof RhinitisWilliam E. Berger, MD, MBA, FACAAI

Topical Therapy for Allergic Rhinitis:Advantages and Underlying MechanismsPhillip L. Lieberman, MD, FACAAI

Emerging Therapies for Allergic and Non-Allergic RhinitisWarner W. Carr, MD, FACAAI

Questions and Discussion

8:30 – 10:30 am

BreakfastSymposium

Allergic Rhinitis:Therapeutic Strategies to Improve

Patient OutcomesModerator: William E. Berger, MD, MBA, FACAAI

With recent estimates suggesting that there has been a rise in allergic reactions, it has become critically important thathealthcare providers are armed with the most up-to-date information on the diagnosis, treatment, and prevention ofanaphylaxis. With 3 sets of clinical guidelines having been released between 2010 and 2011, the ideal source ofinformation on anaphylaxis management remains elusive. In an educational setting, experts can better provide whatmust be known (diagnostic criteria, trigger avoidance, treatment strategies, emergency action plans, etc.) to ensure thatoptimal care is given to patients who are at risk for anaphylaxis, regardless of a patient’s past history or sensitivities to agiven allergic trigger.

Moderator: Sheldon L. Spector, MD, FACAAI, President, American Association of Certified Allergists

11:30 am – 1:30 pm

Recommendations for the Management of Patients With Anaphylaxis:A Consensus Update

11:30 am – 1:30 pm

Jointly Sponsored by the American College of Allergy, Asthma and Immunology (ACAAI)and the American Association of Certified Allergists (AACA)

Target Audience: This activity has been designed for board certified allergists/immunologists and other healthcare providersinvolved in the management of patients with anaphylaxis.

Learning Objectives: Upon completion of this session, participants should be able to: 1) implement evidence-based criteria topromptly recognize and diagnose anaphylaxis; 2) utilize intramuscular epinephrine for the treatment of an anaphylactic episode;3) provide patients and caregivers with education on avoidance of anaphylactic triggers and self-management of anaphylaxis;and 4) create emergency action plans with patients and caregivers that incorporate instructions for self-management.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of theAccreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American College ofAllergy, Asthma & Immunology (ACAAI) and the American Association of Certified Allergists (AACA). The American College ofAllergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) toprovide continuing medical education for physicians.American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 2.0 AMA PRA Category1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AnaphylaxisPhillip L. Lieberman, MD, FACAAI

Critical Issues in the Treatment of Patientswith AnaphylaxisLawrence M. DuBuske, MD, FACAAI

Difficult To Treat Anaphylaxis:Case Study ReviewMarianne Frieri, MD, PhD, FACAAI

Question and Answer Session

Page 10: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Symposia Friday, November 9

9

6:00 – 7:30 pm Corporate8:30 – 10:00 pm Forums

House of Delegates Meeting &Town Hall Forum

4:00 – 6:00 pmPlan to attend the House of Delegates Town Hall Forumwhere all attendees are welcome. Pressing issues inallergy health care will be discussed and everyone’sparticipation is welcomed.

4:00 pm Welcome & Call to OrderLawrence DuBuske, MD, FACAAISpeaker, HODStanley Fineman, MD, MBA, FACAAIACAAI PresidentRichard W. Weber, MD, FACAAIACAAI President-Elect

4:10 pm Approve 2011 HOD Minutes

4:15 pm Update on the JCAAIRichard Honsinger, MD, FACAAIJCAAI President

4:30 pm Accountable Care Organizations andthe Allergy Specialist: Navigatingthe SystemDaniel Ein, MD, FACAAI

4:50 pm Update of Allergen Extracts and theFDA: Where We Stand on SavingOur ExtractsIra Finegold, MD, FACAAI

5:10 pm New Role Proposed for Pharmacists inHealth Care Delivery: Impact onAllergistsBobby Q. Lanier, MD, FACAAI

5:30 pm Quorum Call

5:35 pm Election of Officers

5:40 pm Resolutions

5:50 pm New Business

6:00 pm Adjourn

Update, Diagnosis and Managementof Allergic ConjunctivitisLeonard Bielory, MD, FACAAI

New Treatment Options in theManagement of Seasonal andPerennial Allergic RhinitisWilliam E. Berger, MD, MBA, FACAAI

American Association ofAllergists and Immunologists

of Indian OriginAnnual Meeting and Dinner Symposium

6:00 – 9:00 pm

NOT FORCREDIT

NOT FORCREDIT

NOT FORCREDIT

Register online atwww.acaai.org

Page 11: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Symposia Friday, November 9

10

International Update ofAllergic Diseases

Hispanic-American Allergy, Asthma &Immunology Association

7:00 – 8:30 pm

All participants are cordially invitedto attend this dinner program.

A reception for program participants will immediatelyfollow the educational program.

Other Friday Activities8:00 am – 4:45 pm Advanced Practice Health Care

Providers Course (page 24)8:00 am – 5:30 pm Scientific Workshops (page 17)3:30 – 5:30 pm FIT Program (page 23)5:30 – 6:30 pm FIT Business Meeting (page 23)6:30 – 7:30 pm FIT Welcome Reception (page 23)

Anaheim Orange County Visitor & Convention Bureau video “Walking on Sunshine”.

Page 12: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

General Sessions Saturday, November 10

11

Opening Ceremony andWelcome Announcements

• Stanley M. Fineman, MD, MBA, FACAAIPresident• Richard W. Weber, MD, FACAAIPresident-Elect and Program Chair• Rebecca A. Goldberg, RNAlliance President

7:45 – 8:10 am

When Shortness of BreathIs Not Asthma

Moderators: Bradley E. Chipps, MD, FACAAI andTravis A. Miller, MD, FACAAI

Managing Asthma Patientsin the 21st Century

Moderators: Bryan L. Martin, DO, FACAAI andJohn R. Seyerle, MD

The Role of Vitamin D in Asthma:Pathophysiology and TherapeuticPotentialsMichael B. Foggs, MD, FACAAI

Exhaled Nitric Oxide: Does It Have a Role inAsthma Management?Rohit K. Katial, MD, FACAAI

Practical Issues in Asthma Management:Dealing with Confidence, Compliance, andSatisfactionStanley M. Fineman, MD, MBA, FACAAI

Questions and Discussion

Daniel Goodman Lecture8:10 – 10:30 am

Plenary

Hypersensitivity Pneumonitis/Sarcoidosis: Clinical Presentations &EvaluationJoshua Solomon, MD

Autoimmune Lung Diseases: SLE, RA,and Sjogren’s Syndrome ManagementKevin Brown, MD

Swallowing Disorders & Aspiration:Evaluation & ManagementRichard W. Weber, MD, FACAAI

Questions and Discussion

11:00 am –12:30 pm

Plenary

Allergic Rhinitis: Current and FutureTherapeutic Options for the Allergist

Moderator: Mark S. Dykewicz, MD, FACAAI

The Pharmacological Basis of AllergicRhinitis Management: Past and PresentTherapies – What Have We Learned?Marianne Frieri, MD, PhD, FACAAI

The Pharmacological Basis of AllergicRhinitis Management: EmergingTherapiesLawrence M. DuBuske, MD, FACAAI

Individualizing Therapy for AllergicRhinitis: An Evidence-Based ApproachTodd Mahr, MD, FACAAI

Questions and Discussion

6:00 – 7:30 am

BreakfastSymposium

Asthma Heterogeneity:Phenotypes andEndotypesSally E. Wenzel, MD, FACAAI

The Great AnaphylaxisRaft Debate:

Which Is the Most Important Mediator?Moderators: William K. Dolen, MD, FACAAI and

David R. Weldon, MD, FACAAI

Premise: Experts are adrift in a life raft.There’s enough food and water in the raftfor only one to survive and thesurrounding waters are teeming withsharks. Each expert has exactly 15minutes to make his case. Come and seewho gets tossed to the sharks!

HistaminePhillip L. Lieberman, MD, FACAAI

LeukotrienesLarry Borish, MD, FACAAI

Platelet Activating FactorMitchell H. Grayson, MD, FACAAI

Nitric OxideStephen F. Kemp, MD, FACAAI

Questions and Discussion

1:30 – 3:00 pm

Plenary

Page 13: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

General Sessions Saturday, November 10

12

Early Diagnosis and Treatment ofPrimary Immunodeficiency (PID) inAdults: Insights for the Practicing

Allergist-ImmunologistModerator: TBD

Challenges in Early Diagnosis of PIDin AdultsTBD

PID Presenting in Later Life:Opportunities for Earlier DiagnosisVincent R. Bonagura, MD, PhD

Confirming a Diagnosis of PID in Adults:Current and Future TechnologiesJames Verbsky, MD, PhD

Management of Antibody Deficienciesin Older AdultsMark Ballow, MD, FACAAI

Questions and Discussion

3:30 – 5:30 pm

Symposium

Other Saturday Activities8:00 am – 4:45 pm Allied Health Professionals Course

(pages 25-26)

10:00 am – 5:30 pm Scientific Workshops (pages 17-19)

12:20 – 1:15 pm Program Directors’ Luncheon

12:30 – 1:30 pm Poster Session

President ’sWelcome Reception &Awards Ceremony

7:30 – 9:00 pm

The College invites all registrants to the ACAAIPresident’s Welcome Reception and Awards Ceremonywhere we will recognize our 2012 Award recipientsand formally welcome our newly-approved Fellows.It’s the perfect place to catch up with old friends,make new acquaintances and meet the ACAAIPresident, President-Elect and the Alliance President.

This event will begin at 7:30 pm with food, drinks andmusic and will be followed by a short program whereour new Fellows will be honored for their accomplish-ments and receive their certificates. We will alsorecognize the recipients of the ACAAI’s DistinguishedFellow, International Distinguished Fellow,Distinguished Service, Woman in Allergy, YoungFaculty Support and Von Pirquet Awards.

Finally, we’ll introduce this year’s winner of theCollege’s prestigious Gold Headed Cane Award andinvite the recipient on stage to accept the Award andaddress the audience.

21st AnnualFIT Bowl Competition

Everyone Invited5:00 – 7:00 pm

All physicians, young and old, are invited toparticipate in the most fun-filled learning experienceof the convention. It’s the 21st Annual FIT BowlCompetition.

This entertaining program – patterned after the old“College Bowl” TV quiz show – will pit various allergytraining program teams against each other as theyanswer serious and not-so-serious questions abouttheir specialty. Refreshments and Snacks!

NOT FORCREDIT

Page 14: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

General Sessions Sunday, November 11

13

Diagnosis of Contact Dermatitis: Beyondthe Standard Test PanelKristin M. Leiferman, MD

Dealing Effectively With ContactDermatitis: Avoidance and MoreDonald Belsito, MD

John P. McGovern Lecture8:30 –10:00 am

Plenary

Developing Competence in ContactDermatitis Diagnosis and Treatment

Moderator: David I. Bernstein, MD, FACAAI

Noon – 1:00 pm Poster Session1:00 – 3:00 pm Concurrent Abstract Sessions

3:30 – 5:00 pm

Symposium

Evolving Issues in the Managementof Hereditary Angioedema:Can We Reach a Consensus?

Other Sunday Activities6:30 am – 5:30 pm Scientific Workshops (pages 19-21)7:00 – 8:15 am Meet the Professor Breakfasts (page 16)8:00 am – noon Allied Health Professionals Course

(pages 25-26)Noon – 3:00 pm Doctors’ Job Fair (Registration Form C)7:00 pm Fundraiser Reception and Dinner

(page 28)

10:30 am – noon

PlenaryWhat Does Disturbed Sleep Mean forthe Provider and the Patient?Teofilo Lee-Chiong, MD

The Connection Between DisturbedSleep and Pulmonary HypertensionMichael Littner, MD

The Upper Airway and SleepDisturbanceRichard D. deShazo, MD, FACAAI

Questions and Discussion

Disturbed Sleep Syndromes:More Than Snoring

Moderators: Kevin P. McGrath, MD, FACAAI andMaeve E. O’Connor, MD, FACAAI

Eosinophilic DisordersWorld Allergy Organization (WAO)

Moderators: Ruby U. Pawankar, MD, PhD andStanley M. Fineman, MD, MBA, FACAAI

1:00 – 3:00 pm

SymposiumOverview of Eosinophil BiologyHirohito Kita, MD

Eosinophilic Esophagitis: CurrentInsightsAmal H. Assa’ad, MD, FACAAI

Targeting Eosinophils in Asthma andAllied ConditionsLanny J. Rosenwasser, MD, FACAAI

Questions and DiscussionDefining ContactDermatitis: More ThanJust a RashLuz S. Fonacier, MD, FACAAI

6:15 – 8:15 am

BreakfastSymposium

Ocular AllergyModerator: Leonard Bielory, MD, FACAAI

Check back for further detailsat www.acaai.org

Allergy/immunology specialty physicians play acritical role as a primary resource of informationto guide and coordinate the appropriate care ofpatients with hereditary angioedema (HAE). ThisPractitioner’s Edge symposium will review theevolving and emerging issues in the care ofpatients with HAE with the overall goal ofachieving a management consensus. In addition,the forthcoming international Collaboration forAsthma ALlergy and ImmunoLogy (iCAALL)International Consensus on (ICON) HAE will bereviewed for the first time in this session.

Panelists:Aleena Banerji, MDRichard G. Gower, MD, FACAAIDavid M. Lang, MD, FACAAIWilliam R. Lumry, MD, FACAAI

Page 15: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

General Sessions Monday, November 12

14

Other Monday Activities7:00 – 8:15 am Meet the Professor Breakfasts

(page 16)

8:00 am – 5:30 pm Scientific Workshops (pages 21-22)

Noon – 1:00 pm Women in Medicine Luncheon(page 29)

Maintenance of Certificationand the Allergist

Moderators: Lyndon E. Mansfield, MD, FACAAI andChitra Dinakar, MD, FACAAI

10:30 am – noon

PlenaryThe ABAI MOC Perspective andNavigating the ProcessMary Beth Fasano, MD, FACAAI

The MOC Non-enrolled AllergistCharles J. Siegel, MD, FACAAI

The MOC Compliant AllergistMark L. Corbett, MD, FACAAI

Questions and Discussion

Are There Differences in Urticaria?Moderators: Janna M. Tuck, MD, FACAAI and

Meagan W. Shepherd, MD

Physical & Contact Urticaria: Are TheyDifferent & What Is the Role of FurtherEvaluation?Sandra M. Gawchik, DO, FACAAI

Chronic Urticaria Management: MoreThan AntihistaminesDavid A. Khan, MD, FACAAI

Questions and Discussion

Given in memory of I. Leonard Bernstein, MD

8:30 – 10:00 am

Plenary 3:30 – 5:00 pm

SymposiumOverview of FeNO in thePathophysiology of InflammatoryAirway DiseaseWarner W. Carr, MD, FACAAI

Role of FeNO in the Diagnosis ofAsthma and Non-Specific RespiratorySymptomsNeal Jain, MD

Health Economic Impact of Using FeNOin Asthma Diagnosis and ManagementMyron J. Zitt, MD

Questions and Discussion

Bernard Berman Memorial Lecture

Evaluation andManagement of PruritusWithout RashBobby Q. Lanier, MD, FACAAI

FeNO: A Paradigm Shift inPersonalized Asthma Management

Moderator: James M. Seltzer, MD, FACAAI

What Does History Tell Us: TheBackground on OTCsMichael B. Foggs, MD, FACAAI

The “System” Proposed by FDA Using aNew ParadigmBobby Q. Lanier, MD, FACAAI

The Economic Impact of a New Systemfor the United States Using OtherCountries’ ExperiencesMichael S. Blaiss, MD, FACAAI

The Strategies by Allergists for Adaptingto a New RealityWilliam K. Dolen, MD, FACAAI

Questions and Discussion

6:15 – 8:15 am

BreakfastSymposium

Management of Allergy withNon-Prescription DrugsModerator: Michael B. Foggs, MD, FACAAI

1:00 – 3:00 pm Concurrent AbstractSessions

Page 16: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

General Sessions Tuesday, November 13

15

7:00 – 9:00 am

Stanley M. Fineman, MD, MBA, FACAAI, Presiding

All Registrants Invited9:30 – 11:00 am

PlenaryIntegrative Medicine and Allergy-Immunology: Why Should We Care?Gailen D. Marshall, MD, PhD, FACAAI

Use of Herbals in Our Allergy Practices:Whether You Like It or NotWilliam S. Silvers, MD, FACAAI

Past Presidents’ Breakfastand Annual Business Meeting

Integrative Medicine for theAllergist-ImmunologistModerator: Leonard Bielory, MD, FACAAI

9:00 am

11:00 am Meeting Adjourns

Bela Schick Lecture

The Future of Allergy:What Would Bela Do?James L. Sublett, MD, FACAAI

Anjuli S. Nayak Lecture

Use of Traditional ChineseMedicine in Food AllergyJulie Wang, MD

Photo courtesy of AOCVCB

Page 17: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Meet the Professor BreakfastsSunday & Monday, November 11 & 12

16

M1How to Use Biomarkers in Diagnosisand Treatment of AsthmaDon A. Bukstein, MD, FACAAI andSheldon L. Spector, MD, FACAAI

M2Evaluation of ImmunodeficiencyMark Ballow, MD, FACAAI andVincent R. Bonagura, MD

M3Occupational AsthmaDavid I. Bernstein, MD, FACAAI

M4Indoor AllergensWanda Phipatanakul, MD, FACAAI andJay M. Portnoy, MD, FACAAI

M5Dermatology for the AllergistGerald Gleich, MD andKristin M. Leiferman, MD

M6HAEWilliam R. Lumry, MD, FACAAI andStephen A. Tilles, MD, FACAAI

M7Severe AsthmaDennis K. Ledford, MD, FACAAI

M8Dynamic Dosing in AsthmaBradley E. Chipps, MD, FACAAI andJohn J. Oppenheimer, MD, FACAAI

M9Diagnostic Assessment of AirwayInflammatory PatternsNeal Jain, MD, FACAAI

M10Food Allergy: Controversies inDiagnosisKaren A. DeMuth, MD, FACAAI andChitra Dinakar, MD, FACAAI

Sunday7:00 – 8:15 am

Monday7:00 – 8:15 am

S1What Is the Current Status of SLIT?Michael S. Blaiss, MD, FACAAI andPeter S. Creticos, MD

S2Management of ImmunodeficiencyJordan S. Orange, MD, PhD, FACAAI andJames Verbsky, MD, PhD

S3Assessment of Airway Reactivity:Mannitol vs. MethocholineAidan A. Long, MD andSheldon L. Spector, MD, FACAAI

S4Cough in Children and AdultsAlan Goldsobel, MD, FACAAI andPramod S. Kelkar, MD

S5Chronic RhinosinusitisLarry Borish, MD, FACAAI andTalal M. Nsouli, MD, FACAAI

S6Office Evaluation of Drug AllergyRoland Solensky, MD andTimothy J. Sullivan, MD, FACAAI

S7Eosinophilic Gastrointestinal DiseaseAmal H. Assa’ad, MD, FACAAI andJonathan M. Spergel, MD, PhD, FACAAI

S8All that Wheezes is not AsthmaRohit K. Katial, MD, FACAAI

S9Implications of Local AllergicResponses: EntopyMitchell H. Grayson, MD, FACAAI

S10Food Allergy: Controversies in TherapyA. Wesley Burks, MD, FACAAI

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B • FEE $40 (FITS $20) • LIMIT 30

These informal, small group discussion sessions are designed to facilitate interaction between the presenter and attendees.A continental breakfast is provided and pre-registration is required.

Page 18: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Workshops Friday & Saturday, November 9 & 10

17

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B

W-1A Practical Approach to Aeroallergen Identification8:00 am – 3:00 pmUpon completion of this session, participants should be ableto: 1) set up a sampling station to collect airborne pollen andfungal spores; 2) recognize the most common types of pollenfound in the atmosphere; and 3) discuss the most commontypes of fungal spores found in the atmosphere.Fee: $100 (FITs $50). Lunch on own. Limit 50.Estelle Levetin, PhD and Richard W. Weber, MD, FACAAI

W-2Drug Allergies/Eruptions3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) summarize the basic mechanisms of drug hyper-sensitivity; 2) recognize drug eruptions and differentiate fromother causes; and 3) prepare a treatment plan to manage theseissues more effectively.Fee: $60 (FITs $25). Limit 70.Aleena Banerji, MD and Stephen A. Tilles, MD, FACAAI

W-3Chronic Cough: Pediatrics & Adult3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) describe the common causes of chronic cough andcompare the major differences in pediatric and adult cases;2) distinguish the advantages and disadvantages of diagnostictesting vs. empirical trials of therapy for chronic cough; and3) identify patients with idiopathic chronic cough anddevelop treatment plans utilizing the most effectivetherapeutic options.Fee: $60 (FITs $25). Limit 70.Alan B. Goldsobel, MD, FACAAI and Pramod S. Kelkar, MD

W-4Insect Allergy3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) describe the diagnostic methods for predicting the risk ofanaphylaxis to stings; 2) describe the indications for initiatingvenom immunotherapy (VIT); 3) identify appropriate patientsfor VIT, as well as the dose, regimen and management ofproblems during VIT; and 4) evaluate who should discontinueVIT, when to stop, and the risk factors for relapse.Fee: $60 (FITs $25). Limit 70.Theodore M. Freeman, MD, FACAAI andDavid F. Graft, MD, FACAAI

W-5Skin Biopsy for the Allergist3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) discuss the indications for skin biopsy; 2) examine theuse of punch biopsies to diagnose cutaneous disease;3) demonstrate skills needed to perform a punch biopsywith optimal results; and 4) interpret the skin biopsy andrecognize limitations.Fee: $100 (FITs $50). Limit 70.Marcella R. Aquino, MD and David R. Weldon, MD, FACAAI

W-6Creating a Website for Your Practice10:00 am – noonUpon completion of this session, participants should be ableto: 1) summarize the basic steps to start a website, 2) formulatestrategies to optimize website traffic to help build a practice;3) discuss the advantages as well as the potential medical-legalrisks of online communication with patients; and 4) describethe benefits of a dynamic website to an allergy practice.Fee: $60 (FITs $25). Limit 70.G. David Hopper, MD and J. Allen Meadows, MD, FACAAI

W-7Preparing Your Practice for an EHR1:00 – 3:00 pmUpon completion of this session, participants should be ableto: 1) demonstrate that an office EMR is part of a workflowsolution, not just documentation; 2) explain how to plan forevaluating EMR systems and selecting a vendor; and3) illustrate how staged implementation of EMR increases thelikelihood of success.Fee: $60 (FITs $25). Limit 70.David D. Tanner, MD, FACAAI andRichard L. Wasserman, MD, FACAAI

Y

Y

Y

Y

Y

Saturday

Friday

Learning Objectives are subject to change.

Page 19: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Workshops Saturday, November 10

18

W-8JCAAI Presents 2012 Coding Update3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) discuss CPT codes and requirements for allergists;2) recognize ICD codes for allergy diagnoses; and 3) accesscurrent resources for help with coding.PLEASE NOTE: Workshops W-8 and W-24 will contain much of thesame information.Fee: $60 (FITs $25). Limit 70.Donald W. Aaronson, MD, JD, MPH, FACAAI andGary N. Gross, MD, FACAAI

W-9Patch Testing3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) identify the varied clinical manifestations of contactdermatitis; 2) discuss the rationale behind the nuts and bolts ofallergen patch testing with standard patch tests and extendedpanels; 3) decide what allergen panels may be helpful in thediagnosis of contact sensitivity in specific patient populations;and 4) describe some practical pearls for diagnosis ofcontact dermatitis.Fee: $60 (FITs $25). Limit 70.Marcella R. Aquino, MD, FACAAI, andLuz S. Fonacier, MD, FACAAI

W-10Hot Topics in Pediatric Allergy (SOAI-AAP)3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) review the current literature and discuss recent importantdevelopments in pediatric allergy; and 2) apply recentinformation on the management of insect and drug allergies.Fee: $60 (FITs $25). Limit 70.Chitra Dinakar, MD, FACAAI and Todd A. Mahr, MD, FACAAI

W-11FeNO and Other Biomarkers3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) identify currently available biomarkers to assessinflammation in asthma; 2) describe the role of exhaled nitricoxide and other biomarkers in management of asthma;3) examine the recommendations of the 2011 ATS ClinicalPractice Guideline: Interpretation of Exhaled Nitric Oxide Levelsfor Clinical Application; and 4) interpret exhaled nitric oxidevalues in differing clinical presentations in patients withasthma and other non-specific respiratory symptoms.Fee: $60 (FITs $25). Limit 70.Peter B. Boggs, MD, FACAAI; Neal Jain, MD, FACAAI andMyron J. Zitt, MD, FACAAI

W-12Dermatology Dilemmas: Fascinating Cases to Learn From3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) discuss challenging urticaria and dermatologic cases inthe allergist’s office; 2) discuss some distinguishing features ofdifferent causes of eczema; 3) discuss the distinguishingfeatures that are helpful in diagnosis; and 4) identify differentapproaches to disease work-up as well as the relatedcontroversies.Fee: $60 (FITs $25). Limit 70.Kristin M. Leiferman, MD and Javed Sheikh, MD

W-13Allergy Testing: Optimal Choices and Interpretation3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) describe the current burden of allergic disease and thediagnostic value of allergy skin testing; 2) identify the factorsaffecting variability in skin testing and describe the approvalprocess for an allergy skin test; 3) discuss the most currentpractice parameters on allergy skin testing and use currentlyavailable data to determine which skin test device is best fortheir clinical practice; and 4) better perform, document andinterpret skin testing as well as utilize different forms of skintesting and various devices that can be employed in prickskin testing.Fee: $60 (FITs $25). Limit 70.Bryan L. Martin, DO, FACAAI andJohn J. Oppenheimer, MD, FACAAI

Y

Y

Y

Y

Y

Saturday (continued)

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B

Learning Objectives are subject to change.

Page 20: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Workshops Saturday & Sunday, November 10 & 11

19

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B

W-14Introductory Course in Rhinolaryngoscopy3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) discuss the surgical anatomy of the upper airway,including the nasal cavity, pharynx, and larynx; 2) identifynormal and abnormal anatomy, as well as diseasepresentations and post-operative changes found withendoscopic examination of the upper airway; and 3) identifythe indications for, and the use of, the fiberoptic rhinoscope inthe allergist’s office.Fee: $60 (FITs $25). Limit 70.Seong H. Cho, MD and Jerald W. Koepke, MD, FACAAI

W-15Anaphylaxis Review3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) prepare the office and staff for the treatment ofanaphylaxis; 2) recognize early anaphylaxis due toimmunotherapy; and 3) initiate appropriate treatment withepinephrine and other office-based treatment modalities.Fee: $60 (FITs $25). Limit 70.John M. Kelso, MD, FACAAI andPhillip L. Lieberman, MD, FACAAI

W-16Hands-on Session in Rhinolaryngoscopy6:30 – 8:30 amUpon completion of this session, participants should be ableto: 1) describe the major anatomical structures of the nasal,pharyngeal and glottic areas as visualized during examinationwith the fiber-optic rhinolaryngoscope; 2) describe variationsof normal seen when participants examine one another in thishands-on session; and 3) demonstrate the proper handling andinitial skills needed to perform a comprehensive upper airwayexamination with a fiberoptic endoscope.Prerequisite: Introductory Course in RhinolaryngoscopyFee: $100 (FITs $50). Includes continental breakfast. Limit 30.Jerald W. Koepke, MD, FACAAI; Kevin R. Murphy, MD;Grant C. Olson, MD, FACAAI; Donald W. Pulver, MD, FACAAI;Nathan Segall, MD, FACAAI and C. Ross Westley, MD, FACAAI

W-17Meaningful Use in EHRs and the Health InformationExchange8:00 – 9:45 amUpon completion of this session, participants should be ableto: 1) discuss whether they should have computers in theiroffice or rent space from a remote computer to run theirelectronic medical record system; 2) describe strategies andidentify challenges in successful EHR implementation; and3) discuss EHR implementation as a continual process.Fee: $60 (FITs $25). Limit 70.Russell B. Leftwich, MD, andA. Sean McKnight, MD, FACAAI

W-18Marketing Your Practice Online: Beyond the Basics10:00 am – noonUpon completion of this session, participants should be able to:1) describe what makes a website effective; 2) list examples ofhow to drive more traffic to a practice website; 3) explain whatservices to avoid and determine what questions to ask; and4) discuss how to turn website visitors into patients as well aseffectively implement reputation management for a practice.Fee: $60 (FITs $25). Limit 70.J. Allen Meadows, MD, FACAAI and Brooks Lape

W-19Implementing an EHR Successfully1:00 – 3:00 pmUpon completion of this session, participants should be ableto: 1) discuss whether they should have computers in theiroffice or rent space from a remote computer to run theirelectronic medical record system; 2) describe strategies andidentify challenges in successful EHR implementation; and3) discuss EHR implementation as a continual process.Fee: $60 (FITs $25). Limit 70.Russell B. Leftwich, MD, andDavid J. Shulan, MD, FACAAI

Y

Y

Y

Y

Y

Sunday

Saturday (continued)

Learning Objectives are subject to change.

Page 21: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Workshops Sunday, November 11

20

W-20RADAR Workshop1:00 – 3:00 pmUpon completion of this session, participants should be ableto: 1) discuss that RADAR was formed for the purpose ofregional advocacy with local insurers and government officialsand as a conduit for communication between nationalorganizations and grassroots physicians; 2) describe howRADAR is structured; 3) identify techniques for buildingrelationships with local key leaders as well as effectivelyinteract with insurers and governmental officials; and 4) discussthe role JCAAI will play in their interactions with local entities.Fee: Complimentary. Limit 70.Lawrence M. DuBuske, MD, FACAAI;Richard W. Honsinger, MD, MACP, FACAAI;J. Allen Meadows, MD, FACAAI; andJames M. Tracy, DO, FACAAI

W-21Food Allergy: What’s New!3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) discuss diagnostic tests for food allergy that are currentlyavailable as well as those under development; 2) summarizethe current management and therapies for IgE-mediated foodallergy; 3) review allergen-specific immunotherapy as well asallergen-nonspecific therapy; and 4) discuss key clinical trialsand studies in food allergy treatment.Fee: $60 (FITs $25). Limit 70.Amal H. Assa’ad, MD, FACAAI andA. Wesley Burks, MD, FACAAI

W-22Eosinophilic Gastrointestinal Diseases3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) describe the various forms of eosinophilic gastrointestinaldisorders with emphasis on eosinophilic esophagitis (EoE); 2)recognize the role of the allergist in evaluating EoE by SPT andpatch test; and 3) explain the various treatments of EoEincluding diet and medications.Fee: $60 (FITs $25). Limit 70.Seema S. Aceves, MD andJonathan M. Spergel, MD, PhD, FACAAI

W-23Anaphylaxis: Ready to Roll3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) discuss the problems with the development of a workingdefinition of anaphylaxis and recite the incidence ofanaphylaxis from allergy immunotherapy; 2) discuss the stepsto prepare for and prevent anaphylaxis, as well as the ways torecognize and treat anaphylaxis in the office; 3) discuss pre-cardiac arrest conditions related to anaphylaxis reactions anddiscuss the necessary office preparations to manage cardiacarrest secondary to anaphylaxis; and 4) demonstrate a firstresponder response to cardiac arrest with paramedics.Fee: $60 (FITs $25). Limit 70.Nabil El Sanadi, MD and Dana V. Wallace, MD, FACAAI

W-24JCAAI 2012 Reimbursement and Regulatory Issues3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) effectively manage claims denials from varying insurancecarriers; 2) describe current requirements for meaningful use ofEHR; 3) discuss the importance of compliance with allergy-adopted standards of sterile compounding of allergy extracts;and 4) discuss value-based purchasing.PLEASE NOTE: Workshops W-8 and W-24 will contain much of thesame information.Fee: $60 (FITs $25). Limit 70.Donald W. Aaronson, MD, JD, MPH, FACAAI andGary N. Gross, MD, FACAAI

W-25Occupational Asthma and Dermatitis3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) recognize common occupational asthma and dermatitispresentations; and 2) develop a plan for evaluation andtreatment of occupational asthma and dermatitis.Fee: $60 (FITs $25). Limit 70.Jonathan A. Bernstein, MD, FACAAI andMichael Zacharisen, MD, FACAAI

W-26Statistics Simplified for Clinicians3:30 – 5:30 pmUpon completion of this session, participants should be able toupdate their knowledge of statistics and effectively utilizestatistics in daily practice.Fee: $60 (FITs $25). Limit 70.Sami L. Bahna, MD, DrPH, FACAAI and Steve Conrad, MD, PhD

Y

Y

Y

Sunday (continued)

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B

Learning Objectives are subject to change.

Page 22: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Workshops Sunday & Monday, November 11 & 12

21

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B

W-27Chronic Hypertrophic Sinusitis3:30 – 5:30 pmUpon completion of this session, participants should be able toreview the evaluation and management of chronichypertrophic sinusitis.Fee: $60 (FITs $25). Limit 70.Larry Borish, MD, FACAAI and Eli O. Meltzer, MD, FACAAI

W-28Molecular Biology of Allergens: Towards More AccurateDiagnosis and Treatment3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) explain why tests can be positive for sensitization inpatients who are not sensitive; 2) interpret the clinicalimportance of IgE to components in foods that commonlycause allergic reactions including peanuts, milk, egg, wheat,soy and crustaceans; 3) interpret the clinical importance of IgEto cross-reacting components in aeroallergens and how theyaffect diagnosis and treatment; and 4) interpret the resultsobtained with the ISAC microarray chip to diagnose and treatpatients with complex patterns of IgE sensitization.Fee: $60 (FITs $25). Limit 70.Jay M. Portnoy, MD, FACAAI and P. BrockWilliams, PhD, FACAAI

W-29Immunotherapy Beyond Traditional3:30 – 5:30 pmUpon completion of this session, participants should be able todiscuss traditional and alternative practices in immunotherapy.Fee: $60 (FITs $25). Limit 70.Peter S. Creticos, MD and Charles J. Siegel, MD, FACAAI

W-30EHR Roundtable8:00 – 9:45 amUpon completion of this session, participants should be ableto: 1) identify resources for evaluating and selecting an EHR;2) identify resources for implementing an EHR; and 3) list thebenefits and challenges of EHR adoption.Fee: $60 (FITS $25). Limit 70.Tao T. Le, MD, MHS, FACAAI; David J. Shulan, MD, FACAAI andRichard L. Wasserman, MD, FACAAI

W-31Computerizing the Mixing Lab and Injection Room10:00 am – noonUpon completion of this session, participants should be ableto: 1) discuss conversion from a paper based to electronicmixing lab and shot room; 2) incorporate currentimmunotherapy practice parameters into your electronicmixing lab and shot room; and 3) review currently availableproducts that can be used as stand-alone modules orintegrated into a current EMR.Fee: $60 (FITs $25). Limit 70.Dan A. Dalan, MD, FACAAI andMichael R. Nelson, MD, PhD, FACAAI

W-32Severe Asthma3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) identify subgroups of severe asthma; 2) utilize diagnostictests to establish clear diagnosis of severe asthma; and3) describe the treatment options and approaches for patientswith severe asthma.Fee: $60 (FITs $25). Limit 70.Bradley E. Chipps, MD, FACAAI andDavid M. Lang, MD, FACAAI

W-33Everything You Thought Was Atopic Dermatitis That Wasn’t3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) describe treatments for atopic dermatitis and 2) reviewpatient education tips on caring for atopic dermatitis.Fee: $60 (FITs $25). Limit 70.Marcella R. Aquino, MD, FACAAI andMark Boguniewicz, MD, FACAAI

W-34Immunotherapy: How to Write the Prescription3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) explain the differences between standardized and non-standardized extracts; 2) compose a therapeutic mix forimmunotherapy through review of the literature; 3) write aprescription for immunotherapy that contains effective dosesof each component; and 4) use current guidelines to improvethe safety and effectiveness of immunotherapy in the office.Fee: $60 (FITs $25). Limit 70.Bryan L. Martin, DO, FACAAI andJohn J. Oppenheimer, MD, FACAAI

Y

Y

Y

Y

Y

Monday

Sunday (continued)

Learning Objectives are subject to change.

Page 23: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Workshops Monday, November 12

22

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B

W-35Practical Ocular Examination3:30 – 5:30 pmUpon completion of this session, participants should be able toexecute a complete and relevant ocular examination.Fee: $60 (FITs $25). Limit 70.Anand B. Bhatt, MD and Milton Hom, OD

W-36Basics of a Home Environment Assessment3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) identify criteria for selecting patients who might benefitfrom a home assessment; 2) select a qualified contractor toperform a home assessment and describe the basic assessmentprinciples and general process that occurs when performingthis assessment; 3) describe the environmental measurementsthat can be collected and the equipment typically used forcollecting environmental samples; and 4) interpret a homeassessment report and provide recommendations to patients.Fee: $60 (FITs $25). Limit 70.Kevin Kennedy, CIEC and Jay M. Portnoy, MD, FACAAI

W-37Urticaria and Angioedema: Something Old, Something New3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) discuss the differential diagnosis for urticaria andangioedema and properly assess patients with theseconditions; 2) summarize the current and emerging therapeuticoptions for urticaria and angioedema; 3) describe an evidence-based and cost-effective approach to diagnosis andmanagement of patients with chronic urticaria/angioedema;and 4) identify patients with physical urticaria/angioedemasyndrome.Fee: $60 (FITs $25). Limit 70.Richard G. Gower, MD, FACAAI andWilliam R. Lumry, MD, FACAAI

W-38Immunodeficiency and State Screens: Role of the Allergist3:30 – 5:30 pmUpon completion of this session, participants should be ableto: 1) review immunodeficiency state screens; 2) orderadditional tests; and 3) develop an appropriate treatment plan.Fee: $60 (FITs $25). Limit 70.Stuart L. Abramson, MD and Mark Ballow, MD, FACAAI

Y

Y

Monday (continued)

Learning Objectives are subject to change.

Things to Do in Anaheimhttp://microsite.anaheimoc.org/

attendees/what-to-do

Photo courtesy of AOCVCB/SeaWorld® Adventure Park

Page 24: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Friday

3:30 – 5:30 pm FIT Program – NEWJoin us for two special lectures:Immunodeficiency: Review ofCurrent DataThomas A. Fleisher, MD, FACAAIWhat Will the Future Practice of AllergyLook Like?Bryan L. Martin, DO, FACAAI

5:30 – 6:30 pm FIT Business Meeting

6:30 – 7:30 pm FIT Welcome Reception

Saturday5:00 – 7:00 pm FIT Bowl Competition

7:30 – 9:00 pm ACAAI President’s Welcome Reception andAwards Ceremony

SundayNoon – 3:00 pm Doctors’ Job Fair (Registration Form C)

Fellows-in-Training Friday through Sunday, November 9-11

23

Friday, November 9 • 5:30 – 6:30 pm

Fellows-in-TrainingBusiness Meeting

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM A

5:30 pm Introduction & WelcomeMeagan W. Shepherd, MD, Chair, FIT Committee

5:35 pm ACAAI UpdateStanley M. Fineman, MD, MBA, FACAAI, President

Membership in the ACAAICurtis L. Hedberg, MD, FACAAI andKevin P. McGrath, MD, FACAAICo-Chairs, Membership Recruitment Committee

ACAAI AllianceRebecca A. Goldberg, RN, Alliance President

5:50 pm Faculty DevelopmentBryan L. Martin, DO, FACAAI

ACGME/RRC and FITsDavid B. Peden, MD, FACAAI

JCAAI – Why It’s Important to JoinRichard A. Honsinger, MD, MACP, FACAAIJCAAI President

ABAI CertificationMary Beth Fasano, MD, FACAAI, Chair,The American Board of Allergy and Immunology

6:15 pm FIT SectionUpdateMeagan W. Shepherd, MD,Senior FIT Representative

Candidate Speeches and Election of JuniorFIT Representative

Register online atwww.acaai.org

Page 25: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Advanced Practice Health Care Providers CourseFriday, November 9

24

SEPARATE REGISTRATON FEE • SEE REGISTRATION FORM A OR REGISTER ONLINE AT WWW.ACAAI.ORGTHIS COURSE MAY BE TAKEN ALONE OR IN CONJUNCTION WITH THE ALLIED HEALTH PROFESSIONALS COURSE.

ALLIED STAFF REGISTRANTS THAT ATTEND THE ADVANCED PRACTICE COURSE AND/OR THE ALLIED HEALTH PROFESSIONALS COURSEARE NOT REQUIRED TO PAY THE GENERAL ANNUAL MEETING REGISTRATION FEE.

Target Audience: Nurse practitioners, physician assistants, allergy/immunology nurses, other health care providers with extensiveexperience, and physicians.

Overview: This course is designed for those in advanced practice, including allied health professionals and physicians who want tonetwork with other professionals, interactively learn state-of-the-art treatment of asthma, allergy related dermatologic conditions,hereditary angioedema, recurrent infections, eosinophilic esophagitis, pulmonary function testing, updated pharmacotherapy inallergic and respiratory disease, and the use of technology in patient education.

Learning Objectives: Upon completion of this session, participants should be able to: 1) discuss signs and symptoms, testing andtreatment of recurrent infections; 2) discuss presentation, diagnostic testing and treatment options for hereditary angioedema;3) describe and discuss most common skin rashes seen in an A/A/I office; 4) discuss presentation, testing and treatment of severeand difficult-to-treat asthma; 5) discuss and apply current technology to teach patients in A/A/I practice; 6) discuss and interpretfull pulmonary function testing; 7) identify various presentations for eosinophilic esophagitis; and 8) discuss up-to-datepharmacotherapy for asthma, COPD, allergic rhinoconjunctivitis and sinusitis.

Nursing Accreditation: Provider approved by the California Board of Registered Nursing, Provider Number 14486 for8.7 contact hours.

Interactive ConcurrentWorkshops1:30 – 3:00 pm

ProgramsAP 1-3

General Session8:00 am Introduction

Deidra H. Sanders MSN, FNP

Moderator: Deidra H. Sanders MSN, FNP

8:05 am Recurrent InfectionsPaul V. Williams, MD, FACAAI

8:55 am Angioedema/HAEAleena Banerji, MD

9:45 am Refreshment Break

Moderator: Charlotte M. Jacobsen, RN, MSN

10:00 am Rashes and Itches in an Allergy PracticeDavid R. Weldon, MD, FACAAI

10:50 am Severe and Difficult to Control AsthmaGwen Carlton, DNP, FNP andRay S. Davis, MD, FACAAI

11:40 am Allergy and Asthma Education in an EverChanging World of TechnologyKathy Chojnacki, RN, MSN, CPNP-AC andJodi Shroba, RN, MSN, CPNP

12:30 pm Lunch (on your own)

AP1 Pulmonary Function Testing forAdvanced PracticeMary Kay Bossard BS, RRT, AE-C andConcettina Tolomeo, DNP, AE-C

AP2 Eosinophilic Esophagitis, GER, FPIES:Belly PainSeema S. Aceves, MD, PhD

AP3 Pharmacology for Advanced PracticeMaureen George PhD, RN, AE-C andMary Lou Hayden MS, FNP-BC, AE-C

Refreshment Break

Interactive ConcurrentWorkshops3:15 – 4:45 pm

ProgramsAP 4-6

AP4 Pulmonary Function Testing forAdvanced PracticeMary Kay Bossard BS, RRT, AE-C andConcettina Tolomeo, DNP, AE-C

AP5 Eosinophilic Esophagitis, GER, FPIES:Belly PainSeema S. Aceves, MD, PhD

AP6 Pharmacology for Advanced PracticeMaureen George PhD, RN, AE-C andMary Lou Hayden MS, FNP-BC, AE-C

3:00 pm

Page 26: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Allied Health Professionals CourseSaturday, November 10

25

8:00 am WelcomeDavid A. Khan, MD, FACAAI andMary Lou Hayden, RN, MS, FNP-BC, AE-C

Moderator: Maureen George PhD, RN, AE-C

8:05 am SinusitisSheldon L. Spector, MD, FACAAI

8:55 am Eosinophilic Esophagitis, GER, FPIES: Belly PainSeema S. Aceves, MD, PhD

9:45 am Refreshment Break

SEPARATE REGISTRATION FEE • SEE REGISTRATION FORM A OR REGISTER ONLINE AT WWW.ACAAI.ORGTHIS COURSE MAY BE TAKEN ALONE OR IN CONJUNCTION WITH THE ADVANCED PRACTICE HEALTH CARE PROVIDERS COURSE

ALLIED STAFF REGISTRANTS THAT ATTEND THE ADVANCED PRACTICE COURSE AND/OR THE ALLIED HEALTH PROFESSIONALS COURSEARE NOT REQUIRED TO PAY THE GENERAL ANNUAL MEETING REGISTRATION FEE.

Moderator: Mary Lou Hayden, RN, MS, FNP-BC, AE-C

10:00 am Dermatology in the Allergy OfficeJeannette Arnold, NP

10:50 am Cultural Diversity and Health LiteracyMaureen George PhD, RN, AE-C

11:40 am Questions and Answers/Panel Discussion

Noon Lunch (on your own)

2:00 pm

Saturday Interactive Concurrent Workshops3:30 pm

Saturday Interactive Panels

SA1 Hands-on Basic SpirometryMary Kay Bossard BS, RRT, AE-C andKaren Gregory, DNP, AE-C

SA2 Advanced PFT: What to Order andHow to InterpretConcettina Tolomeo, DNP

SA3 Obstructive Sleep ApneaGwen Carlton, DNP, FNP and Kimberly Clay, NP

SA4 Competency and Procedural SkillsDeidra Sanders, NP andCheryl A. Blackwell, RN

SA5 Allergen Extracts: Evidence-basedVaccinesCheryl Bernstein, BSN

SA6 Pharmacology in Allergy and Asthma:Update and Patient/Family EducationMaureen George PhD, RN, AE-C andMary Lou Hayden, RN, MS, FNP-BC, AE-C

SA7 Hands-on Basic SpirometryMary Kay Bossard BS, RRT, AE-C andKaren Gregory, DNP, AE-C

SA8 Advanced PFT: What to Order andHow to InterpretConcettina Tolomeo, DNP

SA9 Obstructive Sleep ApneaGwen Carlton, DNP, FNP and Kimberly Clay, NP

SA10 Competency and Procedural SkillsDeidra Sanders, NP andCheryl A. Blackwell, RN

SA11 Allergen Extracts: Evidence-based VaccinesCheryl Bernstein, BSN

SA12 Pharmacology in Allergy and Asthma:Update and Patient/Family EducationMaureen George PhD, RN, AE-C andMary Lou Hayden, RN, MS, FNP-BC, AE-C

Target Audience: Allied Health Professionals including, but not limited to RNs, LPN/LVNs, NPs, PAs, RTs, and medical assistants.

Learning Objectives: Upon completion of this activity, participants should be able to: 1) discuss the risk factors and diagnosis ofacute and chronic sinusitis and the pros and cons of pharmacologic and non-pharmacologic treatment; 2) identify variouspresentations and state-of-the-art diagnostic testing and treatment options for eosinophilic esophagitis, vocal cord dysfunction,anaphylaxis, common rashes and ocular allergy; 3) discuss the impact of culture and health literacy and develop culturally andliteracy appropriate educational materials; 4) perform accurate basic spirometry; 5) discuss performance and interpretation ofpulmonary function testing and apply to patient case presentations; 6) discuss risk factors, presentation, and treatment ofobstructive sleep apnea; 7) discuss assessment and update of staff skills in A/A/I practice; 8) discuss current FDA approvedpharmacotherapy in A/A/I practice and appropriate patient/family education; 9) describe ordering, interpretation andpatient/family education associated with most commonly ordered laboratory tests in A/A/I practice.

Accreditation: Provider approved by the California Board of Registered Nursing, Provider Number 14486, for 12.0 contact hours.

4:45 pm Adjourn3:15 pm Refreshment Break

Page 27: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Allied Health Professionals CourseSunday, November 11

26

SEPARATE REGISTRATION FEE • SEE REGISTRATION FORM A OR REGISTER ONLINE AT WWW.ACAAI.ORGTHIS COURSE MAY BE TAKEN ALONE OR IN CONJUNCTION WITH THE ADVANCED PRACTICE HEALTH CARE PROVIDERS COURSE

ALLIED STAFF REGISTRANTS THAT ATTEND THE ADVANCED PRACTICE COURSE AND/OR THE ALLIED HEALTH PROFESSIONALS COURSEARE NOT REQUIRED TO PAY THE GENERAL ANNUAL MEETING REGISTRATION FEE.

10:00 am Vocal Cord Dysfunction: Diagnosisand TreatmentStephen A. Tilles, MD, FACAAI andKaren Drake MA, SLP

10:50 am Common Labs in AllergyChristine Wagner, MSN, CPNP, FNP-BC, AE-C

11:40 am Question and Answer/Panel Discussion

Noon Adjourn

Sunday Interactive PanelsModerator: Gwen Carlton DNP, AE-CModerator: Kimberly Clay, NP

8:00 am Ocular AllergyLeonard Bielory, MD, FACAAI

8:50 am AnaphylaxisDavid A. Khan, MD, FACAAI

9:40 am Refreshment Break

Photo courtesy of Knott’s Berry Farm/AOCVCB

Theme Park Activities forConvention Attendees

http://microsite.anaheimoc.org/attendees/theme-parks-and-attractions/theme-parks

Page 28: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Alliance Programs Friday through Monday, November 9-12

27

The History of Anaheim8:30 – 9:30 am

A historian from the Anaheim Historical Society will present anaccount of Anaheim’s past, its people and highlight things todo during your visit to the city.

Artistic Anaheim8:30 – 9:30 am

A world-renowned Disney artist will talk about past, presentand future public art exhibited in and around Anaheim.

ACAAI KIDS: Learn to Draw9:30 – 10:30 am

A local sketch artist will teach the kids how fun and easydrawing can be. This interactive session will enable thechildren to follow along and practice as they learn. Supplieswill be provided.

Making a Difference, One Bowl of Pasta at a Time8:30 – 9:30 am

Head chef and owner of the Anaheim White Houserestaurant, Bruno Serato, is a local sensation – he’ll tell hisstory of how he became one of CNN’s Top 10 Heroes in 2011!

ACAAI KIDS: Anaheim History for Kids9:30 – 10:30 am

Costumed storytellers will show the kids what life was like inVictorian Anaheim and bring a hands-on activity for them totake home as a memento of their trip.

Sunday, November 11

Saturday, November 10

Active Members of the Allianceare invited to attend the Annual Business

Meeting and LuncheonSunday, November 1112:30 – 3:00 pm

Fee $15 • Registration RequiredLimit 75

Friday, November 9

PLEASE REGISTER ONLINE AT WWW.ACAAI.ORG OR ON REGISTRATION FORM B FOR THE BUSINESS MEETING & LUNCHEON

The following presentations will take place in the Hospitality Suite andare complimentary to registered spouses/guests and families:

The Hospitality Suite at the Anaheim Marriott Hotel will be open forregistered spouses and guests during the following hours:

Friday, Nov. 9 – Monday, Nov. 128:00 – 10:30 am

Page 29: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Fundraising Dinner

28

SEPARATE REGISTRATION FEE • SEE REGISTRATION FORM B OR REGISTER ONLINE AT WWW.ACAAI.ORG

Sunday, November 117:00 pm: Reception • 8:00 pm: Plated Dinner • 9:30 pm: Performance • Tickets Required

Billed by the LA Times as “The Best Beatles Show in the World,” the Fab Four will take you back to when four lads fromLiverpool ruled the world of music! The Fab Fours’ uncanny, note-for-note live renditions of classic Beatles' hits and theirprecise attention to detail will make you think you’re watching the real thing. This dazzling tribute covers every era of theBeatles career and features incredible vocals, vintage guitars and colorful costumes.

You’ll hear record-perfect performances of such classics as, "Can't Buy Me Love," "Yesterday," "A Day In The Life," "Twist AndShout," "Here Comes The Sun," “Back in the USSR” and "Hey Jude." This loving tribute to the Beatles has amazed audiencesaround the world, including Japan, Australia, France, Hong Kong, The United Kingdom, Germany, Mexico and Brazil.

The fundraising program includes a reception, dinner and performance. Net proceeds from the event will be donated tothe ACAAI Foundation to support Fellows-in-Training Program Relief Grants, Young Faculty Support Awards and otherFoundation programs.

Physician Tickets $250 each • Physician Tables $2,300 each • Corporate Tables $10,000 each

Click toview

videos!

Page 30: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Social Events

29

21st AnnualFIT Bowl Competition5:00 – 7:00 pm, Saturday, November 10

Test yourknowledge,sharpen yourwits and jointhe fun atthe dynamic,fast-pacedFIT Bowl.

Participatingteams fromtrainingprogramsaround thecountrycompeteto answer avariety ofserious (and not so serious) questions posed by anexpert panel.

President ’sWelcome Reception &Awards Ceremony7:30 – 9:00 pm, Saturday, November 10

This event begins at 7:30 pm with drinks and lightappetizers and will be followed by a short programwhere we’ll honor our new Fellows for theiraccomplishments and recognize the recipients of theDistinguished Fellow, International Distinguished Fellow,Distinguished Service, Woman in Allergy, Young FacultySupport and Von Pirquet Awards.

Finally, we’ll introduce this year’s winner of theprestigious Gold Headed Cane Award and invite therecipient on stage to address the audience.

Plan to join us for this fun-filled event.

Women in Medicine LuncheonNoon – 1:00 pm, Monday, November 12

Pre-registration is required.

This year’s luncheon will pay tribute to Dr. Kathleen May,who will be recognized for her place not only in theforefront of women in the specialty, but also for hercontributions to the national organization. All womenallergists are invited to attend.

Last year, Wilford Hall Medical Center tookhome the first place trophy, awarded to Drs.Jeremy Sikora (left) and Shayne Stokes.

AllianceInternational Reception6:00 – 7:00 pm, Saturday, November 10

International attendees are cordially invited to attendthe Alliance International Reception on Saturday,November 10, from 6:00 – 7:00 pm, at the AnaheimMarriott.

Anaheim Informationhttp://microsite.anaheimoc.org/

american-college-allergy-asthma-immunology

Visit the ACAAI Aniheim Site for Anaheim information and local attractions.

Page 31: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Things to Do in Anaheim

30

Visitor’s Guide to the Citywww.anaheimoc.org(714) 765-8888

The Anaheim-Orange County Visitor & Convention Bureauwebsite has loads of information on the sights and sounds ofthe city!

Anaheim Tours and Sightseeing Activitieswww.allanaheimtours.comwww.anaheimtours.us

With so much to do and see on your visit, why not let theprofessionals plan your trip for you?

Theme ParksFrom Knott’s Berry Farm, the oldest theme park in the nation,to the original Disneyland and its companion, DisneylandCalifornia Adventure Park, Anaheim is a great place for somegood old-fashioned family fun! Bring your kids to a placewhere imagination becomes reality and their favorite fairytalecharacters are brought to life.

Nearby is the famous Universal Studios Hollywood, whereyou can go behind the scenes and learn just exactly howyour favorite movies are made. Rides, shows, a working moviestudio, shops and restaurants make any visit an all-day,action-packed adventure! Or, take a trip to LEGOLANDCalifornia and explore a world made of Lego bricks.

Just a short distance south is SeaWorld San Diego where youcan come face to face with some of world’s most exotic seacreatures. Dolphins, polar bears, seals, orca and beluga whales,penguins and sharks are just a few of the animals you caninteract with at the park.

For more information, please visit the following websites:Knott’s Berry Farm: www.knotts.comDisneyland/DisneylandCalifornia Adventure Park: www.disneyland.disney.go.comUniversal Studios: www.universalstudioshollywood.comLEGOLAND California: www.california.legoland.comSeaWorld: www.seaworldparks.com

Beachesanaheimoc.org/what-to-do/beaches

With over 40 miles of coastline, Orange County has a beachfor every occasion! Whether you’re looking for an excitingbeach town or a lazy day in the sun, a boardwalk to visit withyour kids or a place to take surfing lessons, there is a beachnear Anaheim just for you.

Discovery Science Centerwww.discoverycube.org

(714) 542-CUBE

If you’re looking for science fun in Orange County, theDiscovery Science Center is the place for you – with morethan 100 hands-on exhibits, the Center lets your imaginationrun wild while you explore the wonderful world of science,from space to dinosaurs, the environment, the supermarketand much, much more.

MUZEOwww.muzeo.org(714) 956-8936

The newest museum in Southern California, MUZEO is housedin Anaheim’s original Carnegie Library, built in 1908, andfeatures a regional history display. The addition of a state-of-the-art gallery space allows the museum to offer changingexhibitions, special events, lectures, classes and weekendfestivals.

Bowers Museumwww.bowers.org(714) 567-3600

Voted the Best Museum in Orange County for 14 consecutiveyears, the Bowers Museum hopes to enrich lives through theworld’s finest arts and cultures. In addition to specialexhibitions and events, the museum’s permanent collectioncontains more than 130,000 works of art and illustrates therich cultural history of many regions of the world.

Newport Landing Whale Watchingwww.newportwhales.com

(949) 675-0551

Located in Newport Harbor, just minutes from Anaheim,Newport Landing offers year-round whale watching trips witha 95 percent success rate of spotting whales and/or dolphins.May through November brings warmer waters to the regionand the chance to see blue, finback and killer whales, as wellas enormous dolphin pods, sharks and seals.

Page 32: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

ZETONNA is a trademark of Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc. is a US subsidiary of Dainippon Sumitomo Pharma Co. Ltd. ©2012 Sunovion Pharmaceuticals Inc. All rights reserved. 8/12 ZETV203-12

Indication: ZETONNA Nasal Aerosol is a corticosteroid indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Important Safety Information: Nasal septal perforation has been reported in patients following the intranasal application of ZETONNA. Nasal septal perforations were reported in 2 patients of 2335 treated with ZETONNA compared with none of 892 treated with placebo. Both perforations occurred in 2-week SAR trials while none occurred in the longer term trials. Before prescribing ZETONNA conduct a nasal examination to ensure that patients are free of nasal disease other than allergic rhinitis. Periodically conduct nasal examinations during treatment. If an adverse reaction (e.g. erosion, ulceration, perforation) is noted, discontinue ZETONNA. Counsel patients that ZETONNA should not be sprayed directly on the nasal septum. Nasal and inhaled corticosteroids may result in the development of glaucoma and cataracts. Close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, or cataracts.

Please see Brief Summary of Prescribing Information on the following pages, or full Prescribing Information at www.zetonna.com.

Prescribe ZETONNA™(ciclesonide) Nasal Aerosol

One spray per nostril, once-daily dry nasal aerosol spray for new

allergic rhinitis patients and those seeking another treatment option

INTRODUCING A NEW DRY NASAL AEROSOL

For patients ages 12 and older su�ering from allergic rhinitists ages 12 a

y nasarry nasal aerosol sprayne sprray p

om alnd older su�ering frrom allera

ayal aerosol sprray for ne, oner nostrill, oncy p

gic rhinitisllerrgic rhinitis

wy for neyilly da-ec

noing akgic rhinrrgic rhinitis pa

tmenother treantients anitis pa

nt optionnd those

ANNOTEZ:noitacidnI acidnidioretsocitrocasilosoreAlasaNA motpmysfotnemtaertehtroffodeta

htrehtoesaesidlasanihwslairtRASkeew-2

pererewsnoitarofforepnIyteffeaStnatropmI

osaeshtiwdetaicossa

ercnifoyrotsihahtiwcaratacdnaamocualg

.mutpeslasanehtnoZeunitnocsid,detonsi

tcudnocyllacidoireP.sitinihrcigrellanaairtmretregnolehtniderruccoenonelihtiwdetaert5332fostneitap2nidetrohnoitarofforeplatpeslasaN:noitamroffon

udanisitinihrcigrellalainnerepdnalan

o,amocualg,erusserpralucoartnidesaapnidetnarrawsignirotinomesolC.stcryamsdioretsocitrocdelahnidnalasaNNNOTEZtahtstneitaplesnuoC.ANNOTEZ

.tnemtaertgnirudsnoitanimaxelasantcudnocANNOTEZgnibircserperoffoeB.sla

298foenonhtiwderapmocANNOTEZhgniwolloffostneitapnidetroperneebsah

dnaegafosraey21stnecselodadnastlupy

.stcaratacrronoisivniegnahcahtiwstneit

fotnempolevedehtnitluseryltceriddeyarpsebtondluohsAN

clu,noisore.g.e(noitcaeresrevdanafI.aptahterusneotnoitanimaxelasanatc

noitarofforephtoB.obecalphtiwdetaertANNOTEZfonoitacilppalasanartniehtg

.redlod

)noitarofforep,noitarecfoeerffrerastneita

niderruccosnlatpeslasaN.A

aeuticvion Pharmacuno©2012 S. isals Inceuticvion PharmacunoS

unoademark of SONNA is a trZET

nIgnibircserPllufromuSfeirBeesesaelP

V203-12. 8/12 ZETedveserts rll righ. Aals Inc.dt. Ltoomo Pharma Cumity of Dainippon Ss a US subsidiar

.als Inceuticvion Pharmac

.moc.annotez.wwwtanoitamroffonnoitamroffonIgnibircserPfoyramm

.,segapgniwolloffoehtno

Page 33: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

ZETONNA™ (ciclesonide) Nasal AerosolFor Intranasal Use OnlyInitial U.S. Approval: 2006BRIEF SUMMARY: Please see package insert for full prescribing information. 1 INDICATIONS AND USAGE

1.1 Treatment of Allergic RhinitisZETONNA™ (ciclesonide) Nasal Aerosol is indicated for the treatment ofsymptoms associated with seasonal and perennial allergic rhinitis in adultsand adolescents 12 years of age and older.

4 CONTRAINDICATIONSZETONNA Nasal Aerosol is contraindicated in patients with a known hyper-sensitivity to ciclesonide or any of the ingredients of ZETONNA NasalAerosol [see Warnings and Precautions (5.3)].

5 WARNINGS AND PRECAUTIONS5.1 Local Nasal EffectsEpistaxis and Nasal Ulceration: In clinical trials of 2 to 26 weeks in duration,epistaxis was observed more frequently in patients treated with ZETONNANasal Aerosol than those who received placebo. In the 26-week open-labelextension of the perennial allergic rhinitis trial, nasal ulceration was identi-fied in 4 of 824 patients administered ZETONNA Nasal Aerosol (148 mcg).[see Adverse Reactions (6)]Nasal Septal Perforation: Nasal septal perforation has been reported inpatients following the intranasal application of ZETONNA Nasal Aerosol.Three short-term placebo-controlled trials (2 weeks) and one long-term (26 weeks with placebo control and 26 weeks open-label extension withoutplacebo control) trial were conducted in patients with seasonal and peren-nial allergic rhinitis. Nasal septal perforations were reported in 2 patientsout of 2335 treated with ZETONNA Nasal Aerosol compared with none of892 treated with placebo.Before starting ZETONNA Nasal Aerosol conduct a nasal examination toensure that patients are free of nasal disease other than allergic rhinitis.Periodically monitor patients with nasal examinations during treatment foradverse effects in the nasal cavity. If an adverse reaction (e.g. erosion,ulceration, perforation) is noted, discontinue ZETONNA Nasal Aerosol.Avoid spraying ZETONNA Nasal Aerosol directly onto the nasal septum.Candida Infection: In clinical trials with another formulation of ciclesonide,the development of localized infections of the nose or pharynx with Candidaalbicans has occurred. If such an infection develops with ZETONNA NasalAerosol, it may require treatment with appropriate local therapy and discon-tinuation of ZETONNA Nasal Aerosol.Impaired Wound Healing: Because of the inhibitory effect of corticosteroidson wound healing, patients who have experienced recent nasal septal ulcers,nasal surgery, or nasal trauma should not use ZETONNA Nasal Aerosol untilhealing has occurred.5.2 Glaucoma and CataractsNasal and inhaled corticosteroids may result in the development of glau-coma and cataracts. Therefore, close monitoring is warranted in patientswith a change in vision or with a history of increased intraocular pressure,glaucoma, or cataracts.5.3 HypersensitivityZETONNA Nasal Aerosol is contraindicated in patients with a known hyper-sensitivity to ciclesonide or any of the ingredients of ZETONNA NasalAerosol. Cases of hypersensitivity reactions following administration ofciclesonide with manifestations such as angioedema, with swelling of thelips, tongue and pharynx, have been reported.5.4 ImmunosuppressionPatients who are using drugs that suppress the immune system are moresusceptible to infections than healthy individuals. Chicken pox and measles,for example, can have a more serious or even fatal course in susceptiblechildren or adults using corticosteroids. In children or adults who have nothad these diseases or been properly immunized, particular care should betaken to avoid exposure. How the dose, route, and duration of cortico -steroid administration affect the risk of developing a disseminated infectionis not known. The contribution of the underlying disease or prior cortico -steroid treatment to the risk is also not known. If a patient is exposed tochicken pox, prophylaxis with varicella zoster immune globulin (VZIG) maybe indicated. If a patient is exposed to measles, prophylaxis with pooledintramuscular immunoglobulin (IG) may be indicated. (See the respectivepackage inserts for complete VZIG and IG prescribing information). Ifchickenpox develops, treatment with antiviral agents may be considered.Corticosteroids should be used with caution, if at all, in patients with activeor quiescent tuberculosis infections of the respiratory tract; or in patientswith untreated local or systemic fungal or bacterial infections; systemicviral or parasitic infections; or ocular herpes simplex because of the poten-tial for worsening of these infections.

5.5 Hypothalamic-Pituitary-Adrenal Axis EffectHypercorticism and Adrenal Suppression: When intranasal corticosteroidsare used at higher than recommended dosages or in susceptible individualsat recommended dosages, systemic corticosteroid effects such as hyper-corticism and adrenal suppression may appear. If such changes occur, thedosage of ZETONNA Nasal Aerosol should be discontinued slowly, consis-tent with accepted procedures for discontinuing oral steroid therapy.The replacement of a systemic corticosteroid with a topical corticosteroidcan be accompanied by signs of adrenal insufficiency. In addition, somepatients may experience symptoms of corticosteroid withdrawal, e.g., jointand muscular pain, lassitude, and depression. Patients previously treatedfor prolonged periods with systemic corticosteroids and transferred to topi-cal corticosteroids should be carefully monitored for acute adrenal insuffi-ciency in response to stress. In those patients who have asthma or otherclinical conditions requiring long-term systemic corticosteroid treatment,rapid decreases in systemic corticosteroid dosages may cause a severeexacerbation of their symptoms.5.6 Effect on GrowthCorticosteroids may cause a reduction in growth velocity when administeredto pediatric patients. Monitor the growth routinely (e.g., via stadiometry) inpediatric patients receiving ZETONNA Nasal Aerosol. [see Pediatric Use (8.4)]

6 ADVERSE REACTIONSSystemic and local corticosteroid use may result in the following:• Epistaxis, ulcerations, nasal septal perforations, Candida albicans infec-

tion, impaired wound healing [see Warnings and Precautions (5.1)]• Glaucoma and cataracts [see Warnings and Precautions (5.2)]• Immunosuppression [see Warnings and Precautions (5.4)]• Hypothalamic-pituitary-adrenal (HPA) axis effects, including growth

reduction [see Warnings and Precautions (5.5, 5.6), Use in Specific Pop-ulations (8.4)]

6.1 Clinical Trials ExperienceThe safety data described below for adults and adolescents 12 years of ageand older are based on 4 clinical trials evaluating doses of ciclesonide nasalaerosol from 74 to 282 mcg. Three of the clinical trials were 2 to 6 weeks induration and one trial was 26 weeks in duration with an additional 26-weekopen-label extension. Data from the first 6 weeks of the 26-week trial werepooled with data from the three 2-week trials. Short-term data (2 to 6 weeks)included 3001 patients with seasonal and perennial allergic rhinitis, ofthese, 884 received ZETONNA Nasal Aerosol 74 mcg once daily and 892received placebo. The short-term data included 1098 (36.6%) males, 1903(63.4%) females, 2587 (86.2%) Caucasians, 320 (10.7%) Blacks, 49 (1.6%)Asians, and 45 (1.5%) patients classified as Other. The 26-week trial wasconducted in 1110 patients with perennial allergic rhinitis [394 (35.5%)males and 716 (64.5%) females, ages 12 to 78 years old] treated withZETONNA Nasal Aerosol 74 mcg, 148 mcg or placebo once daily. Of thesepatients, 298 were treated with 74 mcg ZETONNA Nasal Aerosol, 505 with148 mcg, and 307 with placebo. The racial distribution in this trial included922 (83.1%) Caucasians, 146 (13.2%) Blacks, 18 (1.6%) Asians, and 24(2.2%) patients classified as Other. The 26-week open-label extensionincluded 824 patients [295 (35.8%) males and 529 (64.2%) females, ages12 to 79 years old] given ZETONNA Nasal Aerosol 148 mcg once daily. Theracial distribution in the open-label extension included 690 (83.7%) Cau-casians, 104 (12.6%) Blacks, 15 (1.8%) Asians, and 15 (1.8%) patientsclassified as Other.Because clinical trials are conducted under widely varying conditions,adverse reaction rates observed in clinical trials of a drug cannot be directlycompared to rates in the clinical trials of another drug and may not reflectthe rates observed in practice.Adults and Adolescents 12 Years of Age and Older in Short-Term (2-6 weeks) Trials:In three short-term trials and the first 6 weeks of one long-term trial, con-ducted in the US, 884 patients with a history of seasonal or perennial aller-gic rhinitis were treated with ZETONNA Nasal Aerosol 74 mcg daily. Adversereactions did not differ appreciably based on age, gender, or race. The tablebelow displays reactions that occurred with an incidence of at least 2.0%and more frequently with ZETONNA Nasal Aerosol 74 mcg than with placeboin seasonal or perennial allergic rhinitis clinical trials of 2 to 6 weeks duration.

Page 34: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

Table 1: Adverse Reactions Occurring with a Frequency of at least 2.0% andGreater than Placebo from Controlled Clinical Trials 2 to 6 Weeks inDuration in Patients 12 Years of Age and Older with Seasonal orPerennial Allergic Rhinitis

Adverse Reaction ZETONNA Nasal Aerosol Placebo74 mcg Once Daily

N = 884 (%) N = 892 (%)Nasal discomforta 28 (3.2) 16 (1.8)Headache 27 (3.1) 11 (1.2)Epistaxis 26 (2.9) 24 (2.7)

a Nasal discomfort includes both nasal discomfort and instillation site discomfortWhen considering the data from higher doses evaluated in the short-termtrials, epistaxis demonstrated a dose response. In addition, two patientstreated with ZETONNA Nasal Aerosol 74 mcg experienced nasal septal per-forations in the short-term trials compared to no patients treated withplacebo.Approximately 1.2% of patients treated with ZETONNA Nasal Aerosol 74 mcgin clinical trials discontinued because of adverse reactions; this rate wassimilar for patients treated with placebo.Discontinuations due to local adverse reactions were similar in ZETONNANasal Aerosol 74 mcg treated patients (0.8%) compared to placebo treatedpatients (0.8%). Local adverse reactions leading to discontinuation thatoccurred only in ZETONNA Nasal Aerosol treated patients included earinfection, nasal discomfort, nasal dryness, nasal mucosal/septum disor-ders, pharyngitis, streptococcal pharyngitis, sinus headache, and tonsillitis.Pediatric Patients Aged 2 to 11 Years:Trials of ZETONNA Nasal Aerosol have not been conducted in pediatricpatients aged 2 to 11 years.Long-Term (26-Week Double-Blind and 26-Week Open-Label) Safety Trial:In one 26-week double-blind, placebo-controlled safety trial that included1110 adult and adolescent patients with perennial allergic rhinitis, additionaladverse reactions, with an incidence of at least 2%, that occurred more frequently with ZETONNA Nasal Aerosol than with placebo were upper res-piratory tract infection, urinary tract infection, oropharyngeal pain, nasalmucosal/septum disorders, viral upper respiratory tract infection, cough,influenza, bronchitis, streptococcal pharyngitis, muscle strain, and nausea.Nasal discomfort (5.7%) and epistaxis (11.4%) were also more frequent inthe 26-week safety trial compared to clinical trials 2 to 6 weeks in duration.Nasal mucosal/septum disorders and cough demonstrated a dose response.Discontinuations due to adverse reactions were higher in ZETONNA NasalAerosol treated patients compared to placebo treated patients and demon-strated a dose response. Local adverse reactions leading to discontinuationwere also higher in ZETONNA Nasal Aerosol 74 mcg treated patients (1.7%)compared to placebo treated patients (0.7%). The only local adverse reac-tion leading to discontinuation that occurred in ZETONNA Nasal Aerosoltreated patients and was not observed in the 2- to 6-week trials was upperrespiratory tract infection.A total of 824 patients with perennial allergic rhinitis who completed the 26-week double-blind trial enrolled into an open-label extension and receivedZETONNA Nasal Aerosol 148 mcg for 26 weeks. Additional adverse reactions,observed with an incidence of at least 2% were sinusitis, nasopharyngitis,and back pain.A total of 4 nasal septal ulcerations were also reported in the 26-weekopen-label extension.There were no reports of nasal septal perforations in the long-term safetytrial.6.2 Post-marketing ExperienceAdditional adverse reactions have been identified during worldwide post-marketing use with other formulations of ciclesonide, ALVESCO® InhalationAerosol and OMNARIS® Nasal Spray. Because these reactions are reportedvoluntarily from a population of uncertain size, it is not always possible toreliably estimate their frequency or establish a causal relationship to drugexposure.ALVESCO® Inhalation Aerosol: immediate or delayed hypersensitivity reac-tions such as angioedema with swelling of the lips, tongue, and pharynx.OMNARIS® Nasal Spray: nasal congestion, nasal ulcer, and dizziness.Localized infections of the nose or mouth with Candida albicans have alsooccurred with OMNARIS® Nasal Spray.

7 DRUG INTERACTIONSIn vitro studies and clinical pharmacology studies suggested that des-ciclesonide has no potential for metabolic drug interactions or protein binding-based drug interactions [see Clinical Pharmacology (12.3) in the fullprescribing information]. In a drug interaction study, co-administration oforally inhaled ciclesonide and oral ketoconazole, a potent inhibitor ofcytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide byapproximately 3.6-fold at steady state, while levels of ciclesonide remainedunchanged. Erythromycin, a moderate inhibitor of cytochrome P450 3A4,had no effect on the pharmacokinetics of either des-ciclesonide or erythro-mycin following oral inhalation of ciclesonide [see Clinical Pharmacology(12.3) in the full prescribing information].

8 USE IN SPECIFIC POPULATIONS8.1 PregnancyTeratogenic Effects: Pregnancy Category C.There are no adequate and well-controlled trials in pregnant women.ZETONNA Nasal Aerosol should be used during pregnancy only if thepotential benefit justifies the potential risk to the fetus. Experience with oralcorticosteroids since their introduction in pharmacologic, as opposed tophysiologic, doses suggests that rodents are more prone to teratogeniceffects from corticosteroids than humans.Oral administration of ciclesonide in rats at approximately 120 times themaximum recommended human daily intranasal dose (MRHDID) in adults(on a mcg/m2 basis at a maternal dose of 900 mcg/kg/day) produced noteratogenicity or other fetal effects. However, subcutaneous administrationof ciclesonide in rabbits at similar to MRHDID (on a mcg/m2 basis at amaternal dose of 5 mcg/kg/day) produced fetal toxicity. This included fetalloss, reduced fetal weight, cleft palate, skeletal abnormalities includingincomplete ossifications, and skin effects. No toxicity was observed at ¼ ofthe MRHDID in adults (on a mcg/m2 basis at a maternal dose of 1 mcg/kg/day).Nonteratogenic Effects: Hypoadrenalism may occur in infants born of moth-ers receiving corticosteroids during pregnancy. Such infants should becarefully monitored.8.3 Nursing MothersIt is not known if ciclesonide is excreted in human milk. However, other corticosteroids are excreted in human milk. In a study with lactating rats,minimal but detectable levels of radiolabeled ciclesonide were recovered inmilk. Caution should be used when ZETONNA Nasal Aerosol is administeredto nursing women.8.4 Pediatric UseThe safety and effectiveness for seasonal and perennial allergic rhinitis inchildren 12 years of age and older have been established. The safety andefficacy of ZETONNA Nasal Aerosol for treatment of the symptoms of sea-sonal and perennial allergic rhinitis in patients 11 years of age and youngerhave not been established.Controlled clinical trials have shown that intranasal corticosteroids maycause a reduction in growth velocity in pediatric patients. This effect hasbeen observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression, suggesting that growth velocity isa more sensitive indicator of systemic corticosteroid exposure in pediatricpatients than some commonly used tests of HPA-axis function. The long-term effects of this reduction in growth velocity associated with intranasalcorticosteroids, including the impact on final adult height, are unknown.The potential for “catch-up” growth following discontinuation of treatmentwith intranasal corticosteroids has not been adequately studied. The growthof pediatric patients receiving intranasal corticosteroids, including ZETONNANasal Aerosol, should be monitored routinely (e.g., via stadiometry). A 52-week, multi-center, double-blind, randomized, placebo-controlled parallel-group trial was conducted to assess the effect of orally inhaled ciclesonide(ALVESCO® Inhalation Aerosol) on growth rate in 609 pediatric patientswith mild persistent asthma, aged 5 to 8.5 years. Treatment groupsincluded orally inhaled ciclesonide 40 mcg or 160 mcg or placebo givenonce daily. Growth was measured by stadiometer height during the base-line, treatment and follow-up periods. The primary comparison was the dif-ference in growth rates between ciclesonide 40 and 160 mcg and placebogroups. Conclusions cannot be drawn from this trial because compliancecould not be assured. Ciclesonide blood levels were also not measured duringthe one-year treatment period. There was no difference in efficacy mea -sures between the placebo and the orally inhaled ciclesonide (ALVESCO®

Inhalation Aerosol) groups.

Page 35: 2012 Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (ACAAI)

The potential growth effects of prolonged treatment should be weighedagainst clinical benefits obtained and the availability of safe and effectivenoncorticosteroid treatment alternatives. To minimize the systemic effectsof intranasal corticosteroids, each patient should be titrated to the lowestdose that effectively controls his/her symptoms.The potential for ZETONNA Nasal Aerosol to cause growth suppression insusceptible patients or when given at higher than recommended dosagescannot be ruled out.8.5 Geriatric UseClinical trials of ZETONNA Nasal Aerosol did not include sufficient numbersof patients age 65 and over to determine whether they responded differentlyfrom younger patients. Other reported clinical experience has not identifieddifferences in responses between the elderly and younger patients. In gen-eral, dose selection for an elderly patient should be cautious reflecting thegreater frequency of decreased hepatic, renal, or cardiac function, and ofconcomitant disease or other drug therapy.

10 OVERDOSAGEChronic overdosage may result in signs or symptoms of hypercorticism[see Warnings and Precautions (5.5)]. There are no data on the effects ofacute or chronic overdosage with ZETONNA Nasal Aerosol.

16 STORAGEStore at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [SeeUSP Controlled Room Temp]. For optimal results, canister should be atroom temperature when used.CONTENTS UNDER PRESSUREDo not puncture. Do not use or store near heat or open flame. Exposureto temperatures above 49°C (120°F) may cause bursting. Never throwcanister into fire or incinerator.

Keep out of reach of children. Avoid spraying in eyes or directly onto thenasal septum. ZETONNA Nasal Aerosol 37 mcg, 60 metered actuations; net fill weight6.1 g.NDC Number 63402-737-60

Manufactured for:Sunovion Pharmaceuticals Inc. Marlborough, MA 01752 USA Made in the United Kingdom

ZETONNA is a trademark of Sonovion Pharmaceuticals Inc. SunovionPharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co.Ltd., and is a registered trademark of Dainippon Sunitomo Pharma Co. Ltd©2012 Sunovion Pharmaceuticals Inc. All rights reserved.May 2012CIC066-12For customer service, call 1-888-394-7377To report adverse events, call 1-877-737-7226For medical information, call 1-800-739-0565901641R00620392213